Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases
Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases
复制标题
DOI：
10.3851/imp2792
复制
发表时间：
2015-01-01
影响因子：
1.2
通讯作者：
Al Mutairy, Eid
中科院分区：
文献类型：
--
作者：
Khalid, Mohammed;Al Rabiah, Fahad;Al Mutairy, Eid
中东呼吸综合征冠状病毒（MERS-CoV）是一种新发现的传染性病毒感染，具有高毒力和病死率，目前尚无明确的初级治疗或预防措施。到目前为止，沙特阿拉伯报告的病例数最多。与严重急性呼吸综合征（SARS）一样，MERS是由冠状病毒引起的。干扰素-α 2b和利巴韦林的联合治疗已成功地用作SARS的初级治疗和预防。由于两种冠状病毒之间的相似性，使用利巴韦林和干扰素α 2b治疗已被建议作为MERS-CoV的潜在疗法。在MERS-CoV动物模型中的研究表明，利巴韦林和干扰素-α 2b的组合作为初级治疗和预防都是有效的。在这份报告中，我们首次描述了使用这种组合作为MERS-CoV感染患者的主要治疗方法及其配偶的预防方法，并讨论了其可能的作用。
Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly recognized transmissible viral infection with high virulence and case fatality rates for which there is no currently defined primary treatment or prophylaxis. Saudi Arabia has the largest reported number of cases so far. Like severe acute respiratory syndrome (SARS), MERS is caused by a coronavirus. Combination therapy with interferon-alpha 2b and ribavirin has been used successfully as primary treatment and prophylaxis in SARS. Because of similarities between the two coronaviruses, treatment with ribavarin and interferon-alpha 2b has been suggested as a potential therapy for MERS-CoV. Studies in animal models of MERS-CoV have shown the combination of ribavirin and interferon-alpha 2b to be effective both as primary treatment and prophylaxis. In this report, we describe for the first time use of this combination as a primary treatment for a patient with MERS-CoV infection and as prophylaxis for his spouse and discuss its possible role.